Gilead unit to acquire cell therapy developer Interius for $350 million

Gilead Sciences' Kite Pharma unit is set to acquire privately-held Interius BioTherapeutics for $350 million in cash, aiming to advance CAR T-cell cancer therapies through direct, in-vivo delivery. This acquisition is strategically significant as Interius' platform offers a simpler, intravenous infusion method for cell therapy, potentially reducing the complexity and cost associated with traditional ex-vivo CAR T-cell treatments. While enhancing Kite's oncology pipeline and aligning with surging interest in in-vivo platforms, the deal is projected to reduce Gilead's 2025 earnings per share by $0.23-$0.25.

Analysis

Gilead Sciences, through its Kite Pharma subsidiary, is executing a strategic acquisition of Interius BioTherapeutics for $350 million in cash, securing access to a next-generation "in-vivo" CAR T-cell therapy platform. This move positions Gilead to address the primary drawbacks of its existing approved therapies, Yescarta and Tecartus, which rely on a complex and expensive "ex-vivo" process of extracting, modifying, and re-infusing patient cells. Interius's technology, which uses intravenous infusion for direct DNA delivery, promises to simplify treatment and reduce costs, aligning with a major industry trend that has attracted over $2 billion in recent investment. While strategically positioning Gilead in a high-growth area expected to see over 100 disclosed assets by 2025, the investment comes with a defined near-term financial impact, as the deal is projected to reduce Gilead's 2025 profit per share by approximately $0.23 to $0.25.

Key Decisions for Investors

• Investors should weigh the long-term strategic value of acquiring a potentially disruptive in-vivo cell therapy platform against the clearly stated near-term earnings dilution of $0.23-$0.25 per share for fiscal year 2025.
• The acquisition strengthens Gilead's competitive moat in the highly innovative cell therapy space, positioning it to capitalize on the industry's shift towards simpler and more cost-effective treatments, although the technology is not yet clinically proven.
• Monitor for regulatory approval of the deal and subsequent clinical trial data from the integrated research team to validate the platform's potential and justify the $350 million investment.